SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo
Year: 2026
Type: article
Abstract: The presence of non-neutralizing antibodies of any dengue serotype, increase the severity of subsequent infection by other dengue serotypes. During SARS-CoV-2 pandemic, the number of symptomatic dengue cases increased in India. We describe that antibodies isolated from convalescent plasma from COVID-19 patients enhances DENV2 infection in vitro. CR3022, one antibody against SARS-CoV-2 spike protein, also showed elevated DENV2 infection in vitro. In silico protein-protein interactions between the spike antibodies and the DENV2 E-protein revealed significant interactions. Likewise, few monoclonal/polyclonal antibodies against SARS-CoV-2 showed increased dengue infection in vitro. Importantly, the AG129 mice infected with SARS-CoV-2 three-weeks prior to DENV2 infection, showed elevated dengue pathogenesis. Thus, highlighting the possibilities of elevated infection and symptomatic dengue disease in COVID-19 survivors.
Source: Frontiers in Immunology
Authors: Kamini Jakhar, Sudipta Sonar, Gagandeep Singh, Tejeswara Rao Asuru, Garima Joshi, Nisha Beniwal, Tania Sarkar, Mahima Tiwari, Jaskaran Kaur, Deepak Kumar Rathore, Banwari Lal, Sandeep Kumar, Puneet Srivastav, Satendra Kumar, Vikas Phagna, Sushma Mithina, Lokesh Kumar, Vishal Gupta, Pallavi Kshetrapal, Savita Singh, Nitya Wadhwa, Ramachandran Thiruvengadam, Sreevatsan Raghavan, Mudita Gosain, Tripti Shrivastava, Sankar Bhattacharyya, Shailendra Asthana, Prasenjit Guchhait, Shailendra Mani
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Funders: Bill and Melinda Gates Foundation, Department of Biotechnology, Ministry of Science and Technology, India, Translational Health Science and Technology Institute, National Institutes of Health, Biotechnology Industry Research Assistance Council, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W7124284454